支气管热成形术治疗的重症哮喘患者气道基底干细胞群增大。

IF 5.2 2区 医学 Q1 ALLERGY
Tessa E. Gillett, Sofi M. Vassileva, Els Weersink, Jouke Annema, René Lutter, Martijn C. Nawijn, Maarten van den Berge, Peter I. Bonta, Abilash Ravi
{"title":"支气管热成形术治疗的重症哮喘患者气道基底干细胞群增大。","authors":"Tessa E. Gillett,&nbsp;Sofi M. Vassileva,&nbsp;Els Weersink,&nbsp;Jouke Annema,&nbsp;René Lutter,&nbsp;Martijn C. Nawijn,&nbsp;Maarten van den Berge,&nbsp;Peter I. Bonta,&nbsp;Abilash Ravi","doi":"10.1111/cea.70071","DOIUrl":null,"url":null,"abstract":"<p>Approximately 5% of asthma patients have severe disease, not well-controlled [<span>1</span>] and are treated using biologicals and/or bronchial thermoplasty (BT) [<span>2</span>]. BT applies temperature-controlled radio-frequency energy to medium-sized and larger airways to impact airway remodelling, including reduction of airway smooth muscle and changes in extra-cellular matrix, leading to improved asthma-related quality of life and reduced exacerbations [<span>3</span>]. We previously demonstrated that BT alters metabolism [<span>4</span>] and reduces inflammation [<span>5</span>] in bronchial brushes subjected to RNA-sequencing. During epithelial injury, basal cells can self-renew, differentiate, and drive immune responses along with macrophages and dendritic cells. BT-induced changes in the cell type composition of the bronchial epithelium are unknown. To investigate this, we performed cell type deconvolution on bulk RNA-sequencing data from bronchial brushes collected in the TASMA study [<span>6</span>].</p><p>The TASMA study performed an extensive clinical characterisation and samples were collected before and 6 months after BT, in treated airways and at 6 months in the untreated right middle lobe, but not before from the same subjects. Bronchial brushes were obtained from severe asthma patients (<i>n</i> = 23) in the segmental and subsegmental bronchi and contain sub-types of bronchial epithelium, along with alveolar macrophages, dendritic cells and lymphocytes. The TASMA study design, inclusion and exclusion criteria and methods have been previously described [<span>6</span>]. The study was approved by the Medical Ethics Committee and all subjects gave their written informed consent (NL45394.018.13) [<span>6</span>]. Cell type deconvolution was performed with CIBERSORTx, using single cell RNA-sequencing data of bronchial brushes from the Human Lung Cell Atlas as a reference. Accuracy was validated by deconvolution of HLCA-derived bronchial brush pseudobulk samples of known cell type composition. Additional information on patient characteristics, sample collection, RNA isolation, sequencing and deconvolution analysis are available in the following repository: https://zenodo.org/records/14857109.</p><p>Deconvolution analysis estimated proportions of basal (15.49%), ciliated lineage (ciliated and deuterosomal cells;79.47%), secretory (0.15%), and rare (ionocytes, neuroendocrine and tuft cells;0.24%) epithelial cells, monocytes (0.87%), alveolar (1.78%) and luminal macrophages (0.25%), dendritic cells (1.47%), mast cells (0.23%), B-cell lineage cells (B- and plasma cells;0.05%), and T-, NK and innate lymphoid cells (0.06%) in bronchial brushes of all samples (Figure 1A). We excluded cell types with an estimated proportion of zero in more than 60% of the samples from further statistical analyses. Six months after BT, we found estimated basal cell proportions to be significantly higher in treated compared to untreated regions, from the same patients, whereas the proportions of alveolar macrophages, ciliated lineage cells, and dendritic cells did not differ significantly (Figure 1B). When comparing brushes from the treated lobe obtained before and 6 months after BT, none of the deconvoluted cell types were significantly different (data not shown). This may be partly explained by variability over the 6-month period, e.g., due to seasonal influences and intercurrent infections, which is eliminated by sampling treated and untreated regions at the same time point.</p><p>We previously showed that not all severe asthma patients respond to BT treatment, as defined by a clinically relevant improvement in Asthma Quality of Life Questionnaire score of &gt; 0.5 [<span>6</span>]. The brushes obtained from 23 patients analysed in Figure 1B were separated as responders (<i>n</i> = 11) and non-responders (<i>n</i> = 12). When comparing estimated basal cell proportions in treated versus untreated regions at 6 months after BT, no difference was found between BT responders and non-responders (Figure 1C). Similarly, ciliated lineage cells, alveolar macrophages, and dendritic cells were not significantly different between the two groups (data not shown). To assess proliferation activity of bronchial cells in the treated compared to untreated regions, we analysed the expression of proliferation marker genes <i>PCNA, TOP2A, MKI67</i> and <i>MCM2</i>. No significant differences were observed (data not shown).</p><p>In this study, we show a higher proportion of basal cells in BT-treated regions, which have the capacity to self-renew, transition to committed progenitors, and later differentiate into secretory and ciliated cells [<span>7</span>]. A recent study has shown airway basal cell transplantation's potential as a cell-based therapy for airway epithelial cell damage, illustrating the importance of replenishing basal cells to promote repair and regeneration [<span>8</span>]. Importantly, we validated the signature matrix accuracy; also, estimated cell type proportions were comparable to the proportions identified previously in a single cell (sc)RNA-sequencing dataset of bronchial brushes obtained from asthma patients for another study [<span>9</span>]. Limitations in this study include the lack of bronchial brushes from the untreated right middle lobe at baseline for comparison of changes in cell populations over time in the untreated regions. Therefore, we cannot exclude that changes in the untreated middle lobe over 6 months could have contributed to the observed higher number of basal cells. However, we were able to compare brushes obtained from treated and untreated regions at the same time point, removing the effects of variation over time. No differences were observed between responders and non-responders to BT treatment, which may be due to limited sample size. In this deconvolution analysis, the functional and activation state of the cell types analysed could not be determined. Additional scRNA-sequencing analysis of subtypes of basal cells and mesenchymal cell populations in epithelial brushes and airway biopsies would provide insights into the impact of BT on airway repair and remodelling and/or inflammation. Furthermore, analysis of changes in epithelial populations at earlier time points after BT could be interesting to study effects over time.</p><p>In conclusion, using cell type deconvolution, we show an enlarged basal cell population in bronchial brushes of patients with severe asthma in BT-treated airways compared to untreated airways, which may potentially contribute to the clinical improvement following BT.</p><p>The author takes full responsibility for this article.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 9","pages":"880-882"},"PeriodicalIF":5.2000,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70071","citationCount":"0","resultStr":"{\"title\":\"Airway Basal Stem Cell Population Is Enlarged in Bronchial Thermoplasty Treated Airways in Severe Asthma Patients\",\"authors\":\"Tessa E. Gillett,&nbsp;Sofi M. Vassileva,&nbsp;Els Weersink,&nbsp;Jouke Annema,&nbsp;René Lutter,&nbsp;Martijn C. Nawijn,&nbsp;Maarten van den Berge,&nbsp;Peter I. Bonta,&nbsp;Abilash Ravi\",\"doi\":\"10.1111/cea.70071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Approximately 5% of asthma patients have severe disease, not well-controlled [<span>1</span>] and are treated using biologicals and/or bronchial thermoplasty (BT) [<span>2</span>]. BT applies temperature-controlled radio-frequency energy to medium-sized and larger airways to impact airway remodelling, including reduction of airway smooth muscle and changes in extra-cellular matrix, leading to improved asthma-related quality of life and reduced exacerbations [<span>3</span>]. We previously demonstrated that BT alters metabolism [<span>4</span>] and reduces inflammation [<span>5</span>] in bronchial brushes subjected to RNA-sequencing. During epithelial injury, basal cells can self-renew, differentiate, and drive immune responses along with macrophages and dendritic cells. BT-induced changes in the cell type composition of the bronchial epithelium are unknown. To investigate this, we performed cell type deconvolution on bulk RNA-sequencing data from bronchial brushes collected in the TASMA study [<span>6</span>].</p><p>The TASMA study performed an extensive clinical characterisation and samples were collected before and 6 months after BT, in treated airways and at 6 months in the untreated right middle lobe, but not before from the same subjects. Bronchial brushes were obtained from severe asthma patients (<i>n</i> = 23) in the segmental and subsegmental bronchi and contain sub-types of bronchial epithelium, along with alveolar macrophages, dendritic cells and lymphocytes. The TASMA study design, inclusion and exclusion criteria and methods have been previously described [<span>6</span>]. The study was approved by the Medical Ethics Committee and all subjects gave their written informed consent (NL45394.018.13) [<span>6</span>]. Cell type deconvolution was performed with CIBERSORTx, using single cell RNA-sequencing data of bronchial brushes from the Human Lung Cell Atlas as a reference. Accuracy was validated by deconvolution of HLCA-derived bronchial brush pseudobulk samples of known cell type composition. Additional information on patient characteristics, sample collection, RNA isolation, sequencing and deconvolution analysis are available in the following repository: https://zenodo.org/records/14857109.</p><p>Deconvolution analysis estimated proportions of basal (15.49%), ciliated lineage (ciliated and deuterosomal cells;79.47%), secretory (0.15%), and rare (ionocytes, neuroendocrine and tuft cells;0.24%) epithelial cells, monocytes (0.87%), alveolar (1.78%) and luminal macrophages (0.25%), dendritic cells (1.47%), mast cells (0.23%), B-cell lineage cells (B- and plasma cells;0.05%), and T-, NK and innate lymphoid cells (0.06%) in bronchial brushes of all samples (Figure 1A). We excluded cell types with an estimated proportion of zero in more than 60% of the samples from further statistical analyses. Six months after BT, we found estimated basal cell proportions to be significantly higher in treated compared to untreated regions, from the same patients, whereas the proportions of alveolar macrophages, ciliated lineage cells, and dendritic cells did not differ significantly (Figure 1B). When comparing brushes from the treated lobe obtained before and 6 months after BT, none of the deconvoluted cell types were significantly different (data not shown). This may be partly explained by variability over the 6-month period, e.g., due to seasonal influences and intercurrent infections, which is eliminated by sampling treated and untreated regions at the same time point.</p><p>We previously showed that not all severe asthma patients respond to BT treatment, as defined by a clinically relevant improvement in Asthma Quality of Life Questionnaire score of &gt; 0.5 [<span>6</span>]. The brushes obtained from 23 patients analysed in Figure 1B were separated as responders (<i>n</i> = 11) and non-responders (<i>n</i> = 12). When comparing estimated basal cell proportions in treated versus untreated regions at 6 months after BT, no difference was found between BT responders and non-responders (Figure 1C). Similarly, ciliated lineage cells, alveolar macrophages, and dendritic cells were not significantly different between the two groups (data not shown). To assess proliferation activity of bronchial cells in the treated compared to untreated regions, we analysed the expression of proliferation marker genes <i>PCNA, TOP2A, MKI67</i> and <i>MCM2</i>. No significant differences were observed (data not shown).</p><p>In this study, we show a higher proportion of basal cells in BT-treated regions, which have the capacity to self-renew, transition to committed progenitors, and later differentiate into secretory and ciliated cells [<span>7</span>]. A recent study has shown airway basal cell transplantation's potential as a cell-based therapy for airway epithelial cell damage, illustrating the importance of replenishing basal cells to promote repair and regeneration [<span>8</span>]. Importantly, we validated the signature matrix accuracy; also, estimated cell type proportions were comparable to the proportions identified previously in a single cell (sc)RNA-sequencing dataset of bronchial brushes obtained from asthma patients for another study [<span>9</span>]. Limitations in this study include the lack of bronchial brushes from the untreated right middle lobe at baseline for comparison of changes in cell populations over time in the untreated regions. Therefore, we cannot exclude that changes in the untreated middle lobe over 6 months could have contributed to the observed higher number of basal cells. However, we were able to compare brushes obtained from treated and untreated regions at the same time point, removing the effects of variation over time. No differences were observed between responders and non-responders to BT treatment, which may be due to limited sample size. In this deconvolution analysis, the functional and activation state of the cell types analysed could not be determined. Additional scRNA-sequencing analysis of subtypes of basal cells and mesenchymal cell populations in epithelial brushes and airway biopsies would provide insights into the impact of BT on airway repair and remodelling and/or inflammation. Furthermore, analysis of changes in epithelial populations at earlier time points after BT could be interesting to study effects over time.</p><p>In conclusion, using cell type deconvolution, we show an enlarged basal cell population in bronchial brushes of patients with severe asthma in BT-treated airways compared to untreated airways, which may potentially contribute to the clinical improvement following BT.</p><p>The author takes full responsibility for this article.</p><p>The authors declare no conflicts of interest.</p>\",\"PeriodicalId\":10207,\"journal\":{\"name\":\"Clinical and Experimental Allergy\",\"volume\":\"55 9\",\"pages\":\"880-882\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70071\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cea.70071\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cea.70071","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

大约5%的哮喘患者病情严重,不能很好地控制[1],并使用生物制剂和/或支气管热成形术(BT)[1]进行治疗。BT将温度控制的射频能量应用于中型和大型气道,以影响气道重塑,包括气道平滑肌的减少和细胞外基质的改变,从而改善哮喘相关的生活质量,减少恶化[3]。我们之前通过rna测序证明了BT改变了支气管刷的代谢[5]并减少了炎症[5]。在上皮损伤过程中,基底细胞可以自我更新、分化,并与巨噬细胞和树突状细胞一起驱动免疫反应。bt诱导支气管上皮细胞类型组成的改变尚不清楚。为了研究这一点,我们对在TASMA研究中收集的支气管刷的大量rna测序数据进行了细胞类型反褶积。TASMA研究进行了广泛的临床表征,并在BT治疗前和6个月后,在治疗气道和6个月时在未治疗的右中叶收集样本,但在此之前没有从同一受试者中收集样本。支气管刷取自重度哮喘患者(n = 23)的支气管段和亚段支气管,含有支气管上皮亚型,以及肺泡巨噬细胞、树突状细胞和淋巴细胞。TASMA研究的设计、纳入和排除标准和方法已在之前的文献中描述[b]。本研究经医学伦理委员会批准,所有受试者均给予书面知情同意(NL45394.018.13)[6]。使用CIBERSORTx进行细胞类型反卷积,以Human Lung Cell Atlas中支气管刷的单细胞rna测序数据为参考。准确性通过对已知细胞类型组成的hlca衍生支气管刷假体样品进行反褶积验证。关于患者特征、样本收集、RNA分离、测序和反褶积分析的更多信息可在以下存储库中获得:https://zenodo.org/records/14857109.Deconvolution分析估计了基底细胞(15.49%)、纤毛细胞谱系(纤毛细胞和后染色体细胞;79.47%)、分泌细胞(0.15%)和稀有(离子细胞、神经内分泌细胞和簇状细胞;0.24%)上皮细胞、单核细胞(0.87%)、肺泡(1.78%)和腔内巨噬细胞(0.25%)、树突状细胞(1.47%)、肥大细胞(0.23%)、B细胞谱系细胞(B-和浆细胞;0.05%)和T-、所有样本支气管刷中NK细胞和先天淋巴样细胞(0.06%)(图1A)。我们从进一步的统计分析中排除了60%以上样本中估计比例为零的细胞类型。在接受BT治疗6个月后,我们发现在相同的患者中,治疗区域的基底细胞比例明显高于未治疗区域,而肺泡巨噬细胞、纤毛谱系细胞和树突状细胞的比例没有显著差异(图1B)。当比较治疗前和治疗后6个月的脑叶刷时,没有任何去卷积的细胞类型有显著差异(数据未显示)。这在一定程度上可以解释为6个月期间的变异性,例如,由于季节性影响和并发感染,通过在同一时间点对治疗和未治疗区域进行采样可以消除这种情况。我们之前的研究表明,并非所有严重哮喘患者都对BT治疗有反应,哮喘生活质量问卷评分的临床相关改善为0.5[6]。从图1B中分析的23例患者中获得的刷子被分为有反应者(n = 11)和无反应者(n = 12)。在BT后6个月比较治疗区和未治疗区估计的基底细胞比例时,发现BT应答者和无应答者之间没有差异(图1C)。同样,纤毛谱系细胞、肺泡巨噬细胞和树突状细胞在两组之间没有显著差异(数据未显示)。为了评估支气管细胞的增殖活性,我们分析了增殖标记基因PCNA、TOP2A、MKI67和MCM2的表达。未观察到显著差异(数据未显示)。在这项研究中,我们发现在bt处理区域有更高比例的基底细胞,它们具有自我更新的能力,转化为固定的祖细胞,然后分化为分泌细胞和纤毛细胞[7]。最近的一项研究表明,气道基底细胞移植作为一种基于细胞的治疗气道上皮细胞损伤的潜力,说明了补充基底细胞对促进气道上皮细胞修复和再生的重要性。 重要的是,我们验证了签名矩阵的准确性;此外,估计的细胞类型比例与先前在另一项研究[9]中从哮喘患者获得的支气管刷的单细胞(sc) rna测序数据集中确定的比例相当。本研究的局限性包括在基线时缺乏未经治疗的右中叶的支气管刷,无法比较未经治疗区域细胞群随时间的变化。因此,我们不能排除6个月未治疗的中叶的变化可能导致观察到的基底细胞数量增加。然而,我们能够比较在同一时间点从处理和未处理地区获得的刷子,消除随时间变化的影响。对BT治疗有反应者和无反应者之间没有观察到差异,这可能是由于样本量有限。在这种反褶积分析中,无法确定所分析的细胞类型的功能和激活状态。对上皮刷和气道活检中基底细胞和间充质细胞群亚型的额外scrna测序分析将有助于深入了解BT对气道修复、重塑和/或炎症的影响。此外,分析BT后早期时间点上皮细胞群体的变化可能会对研究随时间的影响很有趣。总之,通过细胞类型反褶积,我们发现,与未治疗的气道相比,接受bt治疗的气道中严重哮喘患者的支气管刷中基底细胞数量增加,这可能有助于bt治疗后的临床改善。作者声明无利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Airway Basal Stem Cell Population Is Enlarged in Bronchial Thermoplasty Treated Airways in Severe Asthma Patients

Airway Basal Stem Cell Population Is Enlarged in Bronchial Thermoplasty Treated Airways in Severe Asthma Patients

Approximately 5% of asthma patients have severe disease, not well-controlled [1] and are treated using biologicals and/or bronchial thermoplasty (BT) [2]. BT applies temperature-controlled radio-frequency energy to medium-sized and larger airways to impact airway remodelling, including reduction of airway smooth muscle and changes in extra-cellular matrix, leading to improved asthma-related quality of life and reduced exacerbations [3]. We previously demonstrated that BT alters metabolism [4] and reduces inflammation [5] in bronchial brushes subjected to RNA-sequencing. During epithelial injury, basal cells can self-renew, differentiate, and drive immune responses along with macrophages and dendritic cells. BT-induced changes in the cell type composition of the bronchial epithelium are unknown. To investigate this, we performed cell type deconvolution on bulk RNA-sequencing data from bronchial brushes collected in the TASMA study [6].

The TASMA study performed an extensive clinical characterisation and samples were collected before and 6 months after BT, in treated airways and at 6 months in the untreated right middle lobe, but not before from the same subjects. Bronchial brushes were obtained from severe asthma patients (n = 23) in the segmental and subsegmental bronchi and contain sub-types of bronchial epithelium, along with alveolar macrophages, dendritic cells and lymphocytes. The TASMA study design, inclusion and exclusion criteria and methods have been previously described [6]. The study was approved by the Medical Ethics Committee and all subjects gave their written informed consent (NL45394.018.13) [6]. Cell type deconvolution was performed with CIBERSORTx, using single cell RNA-sequencing data of bronchial brushes from the Human Lung Cell Atlas as a reference. Accuracy was validated by deconvolution of HLCA-derived bronchial brush pseudobulk samples of known cell type composition. Additional information on patient characteristics, sample collection, RNA isolation, sequencing and deconvolution analysis are available in the following repository: https://zenodo.org/records/14857109.

Deconvolution analysis estimated proportions of basal (15.49%), ciliated lineage (ciliated and deuterosomal cells;79.47%), secretory (0.15%), and rare (ionocytes, neuroendocrine and tuft cells;0.24%) epithelial cells, monocytes (0.87%), alveolar (1.78%) and luminal macrophages (0.25%), dendritic cells (1.47%), mast cells (0.23%), B-cell lineage cells (B- and plasma cells;0.05%), and T-, NK and innate lymphoid cells (0.06%) in bronchial brushes of all samples (Figure 1A). We excluded cell types with an estimated proportion of zero in more than 60% of the samples from further statistical analyses. Six months after BT, we found estimated basal cell proportions to be significantly higher in treated compared to untreated regions, from the same patients, whereas the proportions of alveolar macrophages, ciliated lineage cells, and dendritic cells did not differ significantly (Figure 1B). When comparing brushes from the treated lobe obtained before and 6 months after BT, none of the deconvoluted cell types were significantly different (data not shown). This may be partly explained by variability over the 6-month period, e.g., due to seasonal influences and intercurrent infections, which is eliminated by sampling treated and untreated regions at the same time point.

We previously showed that not all severe asthma patients respond to BT treatment, as defined by a clinically relevant improvement in Asthma Quality of Life Questionnaire score of > 0.5 [6]. The brushes obtained from 23 patients analysed in Figure 1B were separated as responders (n = 11) and non-responders (n = 12). When comparing estimated basal cell proportions in treated versus untreated regions at 6 months after BT, no difference was found between BT responders and non-responders (Figure 1C). Similarly, ciliated lineage cells, alveolar macrophages, and dendritic cells were not significantly different between the two groups (data not shown). To assess proliferation activity of bronchial cells in the treated compared to untreated regions, we analysed the expression of proliferation marker genes PCNA, TOP2A, MKI67 and MCM2. No significant differences were observed (data not shown).

In this study, we show a higher proportion of basal cells in BT-treated regions, which have the capacity to self-renew, transition to committed progenitors, and later differentiate into secretory and ciliated cells [7]. A recent study has shown airway basal cell transplantation's potential as a cell-based therapy for airway epithelial cell damage, illustrating the importance of replenishing basal cells to promote repair and regeneration [8]. Importantly, we validated the signature matrix accuracy; also, estimated cell type proportions were comparable to the proportions identified previously in a single cell (sc)RNA-sequencing dataset of bronchial brushes obtained from asthma patients for another study [9]. Limitations in this study include the lack of bronchial brushes from the untreated right middle lobe at baseline for comparison of changes in cell populations over time in the untreated regions. Therefore, we cannot exclude that changes in the untreated middle lobe over 6 months could have contributed to the observed higher number of basal cells. However, we were able to compare brushes obtained from treated and untreated regions at the same time point, removing the effects of variation over time. No differences were observed between responders and non-responders to BT treatment, which may be due to limited sample size. In this deconvolution analysis, the functional and activation state of the cell types analysed could not be determined. Additional scRNA-sequencing analysis of subtypes of basal cells and mesenchymal cell populations in epithelial brushes and airway biopsies would provide insights into the impact of BT on airway repair and remodelling and/or inflammation. Furthermore, analysis of changes in epithelial populations at earlier time points after BT could be interesting to study effects over time.

In conclusion, using cell type deconvolution, we show an enlarged basal cell population in bronchial brushes of patients with severe asthma in BT-treated airways compared to untreated airways, which may potentially contribute to the clinical improvement following BT.

The author takes full responsibility for this article.

The authors declare no conflicts of interest.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.40
自引率
9.80%
发文量
189
审稿时长
3-8 weeks
期刊介绍: Clinical & Experimental Allergy strikes an excellent balance between clinical and scientific articles and carries regular reviews and editorials written by leading authorities in their field. In response to the increasing number of quality submissions, since 1996 the journals size has increased by over 30%. Clinical & Experimental Allergy is essential reading for allergy practitioners and research scientists with an interest in allergic diseases and mechanisms. Truly international in appeal, Clinical & Experimental Allergy publishes clinical and experimental observations in disease in all fields of medicine in which allergic hypersensitivity plays a part.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信